Navigation Links
Cancer screening rates comparable for those with and without rheumatoid arthritis
Date:7/9/2012

New research reveals that rheumatoid arthritis (RA) patients do not receive fewer cancer screening tests than the general population. Results of the study, funded in part by grants from the National Institutes of Health (NIH) and published in Arthritis & Rheumatism, a journal of the American College of Rheumatology (ACR), found that RA and non-RA patients receive routine screening for breast, cervical, and colon cancer at similar rates.

The ACR estimates that 1.3 million adult Americans are affected by RAa chronic autoimmune disease characterized by systemic inflammation of the joints that over time may damage joints, impair daily function, and cause significant disability. Medical evidence confirms that despite early and aggressive treatment, RA patients have a decreased life expectancy compared to the general population. Previous research reports that cancer is one of the main causes of death for RA patients and patients with chronic disease may not receive preventive medical services including regular screenings for cancer.

"Early detection of common cancers can improve morbidity and mortality rates in those with chronic illnesses, such as RA," said Dr. Seoyoung C. Kim with the Division of Rheumatology and Division of Pharmacoepidemiology at Brigham and Women's Hospital in Boston, Mass. "Cancer screening tests are important in detecting malignancies at early stages for both chronically ill and healthy populations."

To further understand barriers to preventative medical care and raise awareness of the importance of early cancer screenings, Dr. Kim and colleagues examined screening rates for breast, cervical and colon cancer in RA patient compared to those without the disease. Using claims data from a major insurance provider, the team identified 13,314 patients with RA patients and 212,324 non-RA patients.

Analysis shows that on average both RA and non-RA groups were screened once every three years for cervical cancer and every two years for breast cancer. Among all participants 50 years and older, 12% of RA patients and 10% of non-RA patients had at least one colonoscopy each year. Women with RA were more likely to have an annual Pap smear, mammogram, fecal occult blood (FOB) test and colonoscopy than those without RA. Male RA patients were also more likely to have a colonoscopy compared to than those without RA.

"Our findings indicate that RA patients were regularly screened for cervical, breast and colon cancer as recommended by the American Cancer Society," concludes Dr. Kim. "Cancer screenings rates among patients with RA were similar to the general population, which is different than previously published results. However, these earlier studies did not compare rates of cancer screenings in RA patients with a non-RA group." The authors suggest that patients and physicians be aware of the importance of preventive healthcare in patients with chronic diseases such as RA. They caution that results of this should not be generalized to those without medical insurance.


'/>"/>

Contact: Dawn Peters
sciencenewsroom@wiley.com
781-388-8408
Wiley
Source:Eurekalert

Related medicine news :

1. Regulation by proteins outside cancer cells points to potential new drug target
2. Decreasing cancer risk associated with inflammatory bowel disease
3. Better treatment for brain cancer revealed by new molecular insights
4. Researchers find new target deep within cancer cells
5. Cell differentiation as a novel strategy for the treatment of an aggressive type of skin cancer
6. Ovarian Transplants May Preserve Fertility in Young Cancer Survivors
7. Fertility drug usage and cancer risk
8. Scientists develop mouse model that could lead to new therapies for liver cancer
9. Can Fertility Treatments Influence Later Breast Cancer Risk?
10. Worlds fastest camera, created by UCLA engineers, used to detect rogue cancer cells
11. Loss of protein SPDEF allows prostate cancer cells to gain foothold at possible sites of metastasis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... PurhealthRX , a leading Health and Nutrition ... the Purzorb™process to full spectrum CBD oil will revolutionize the rapidly growing CBD market ... can be easily incorporated into liquid products, while reducing costs to end users. , ...
(Date:10/13/2017)... ... October 13, 2017 , ... Apple Rehab Shelton Lakes , ... mock evacuation of the facility as part of a disaster drill on October 3rd. ... EMS and Shelton City Emergency Manager, as well as the Connecticut Long Term ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading ... to advocate for action towards gender equality at their inaugural Summit in New York ... globe, and reached a social audience of over 3 million. To watch the Mobilize ...
(Date:10/13/2017)... ... October 13, 2017 , ... Talented host, actor Rob Lowe, ... in a new episode of "Success Files," which is an award-winning educational program ... investigates each subject in-depth with passion and integrity. , Sciatica occurs when the ...
(Date:10/13/2017)... (PRWEB) , ... October 13, 2017 , ... “America On ... Christian identity. “America On The Brink” is the creation of published author, William ... several great-grandchildren. As a WWII veteran, he spent thirty years in the Navy. ...
Breaking Medicine News(10 mins):
(Date:9/27/2017)...  Commended for their devotion to personalized service, SMP Pharmacy ... one in the South Florida Business Journal,s 50 Fastest-Growing Companies, ... list, the national specialty pharmacy has found its niche.  To ... soon be honored by SFBJ as the 2017 Power Leader ... to receive his award in October, Bardisa said of the ...
(Date:9/25/2017)... --  Montrium , an industry leader in powerful ... Trial Master Files & Inspection Readiness Conference ( ... Services has selected eTMF Connect to ... a leading European contract research organization (CRO), will ... enable greater collaboration with sponsors, improve compliance and ...
(Date:9/23/2017)... 22, 2017 Janssen Biotech, Inc. (Janssen) announced ... from the U.S. Food and Drug Administration (FDA) for ... for the treatment of moderately to severely active rheumatoid ... data are needed to further evaluate the safety of ... RA. "We ...
Breaking Medicine Technology: